This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XenoPort's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Question-and-Answer Session

David Friedman - Morgan Stanley

Maybe we can start quickly with AP, the spasticity drug. You guys had positive Phase II data there and a slightly different population, so for people that may or may not have been following along with this program, can you just briefly describe what types of data you are looking to generate out of the Phase III program, and whether you see a lot of risk going from spinal cord injury to MS, or is spasticity given the underlying pathology.

Ron Barrett

I think most experts in the field would say that spasticity response to treatment independent of the original [neurology] of the spasticity, whether it's spinal cord, whether it's MS stroke or traumatic brain injury, and there are differences in the patient population, the spinal cord injury population, typically that's had spasticity for longer.

Multiple sclerosis patients obviously lot of things going with their disease progression, and it's the reason why we really took pretty stringent requirements of patient selection that's taken us while to recruit the right patients. We're requiring certain minimal level of spasticity, minimal level of disability and a maximum level of disability. We are looking at the spasticity to measurement of what's called the Ashworth Score.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs